AR112900A1 - Compuesto derivado de pirazol y uso de este - Google Patents
Compuesto derivado de pirazol y uso de esteInfo
- Publication number
- AR112900A1 AR112900A1 ARP180102593A ARP180102593A AR112900A1 AR 112900 A1 AR112900 A1 AR 112900A1 AR P180102593 A ARP180102593 A AR P180102593A AR P180102593 A ARP180102593 A AR P180102593A AR 112900 A1 AR112900 A1 AR 112900A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- unsubstituted
- linked
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000003386 piperidinyl group Chemical group 0.000 abstract 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 3
- 230000003287 optical effect Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000003725 azepanyl group Chemical group 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos que tienen una actividad inhibidora de la desmetilasa-1 específica de lisina (LSD1), un isómero óptico, un solvato, un tautómero o una sal farmacéuticamente aceptable de estos que es eficaz para prevenir o tratar una enfermedad provocada por la activación anómala de LSD1. Reivindicación 1: Un compuesto representado por la fórmula (1), un isómero óptico, un solvato o un tautómero o una sal farmacéuticamente aceptable de este, caracterizado porque, en la fórmula (1), el anillo B es un grupo carbocíclico C₃₋₃₀ o un grupo heterocíclico C₁₋₃₀; X es C(R⁵) o N; cada uno de R¹(s) a R⁵ es independientemente un radical monovalente seleccionado entre hidrógeno, halógeno, un grupo ciano, un grupo hidroxi, un grupo tiol, un grupo nitro, un grupo alquilo C₁₋₂₀ sustituido o no sustituido, un grupo alquenilo C₂₋₂₀ sustituido o no sustituido, un grupo alquinilo C₂₋₂₀ sustituido o no sustituido, un grupo carbocíclico C₃₋₂₀ sustituido o no sustituido, un grupo heterocíclico C₁₋₂₀ sustituido o no sustituido, un grupo alcoxi C₁₋₂₀ sustituido o no sustituido, un grupo cicloalcoxi C₃₋₂₀ sustituido o no sustituido, un grupo alquiltio C₁₋₂₀ sustituido o no sustituido, un grupo ariloxi C₆₋₂₀ sustituido o no sustituido, un grupo ariltio C₆₋₂₀ sustituido o no sustituido, un grupo heteroariloxi C₁₋₂₀ sustituido o no sustituido, un grupo heteroariltio C₁₋₂₀ sustituido o no sustituido, un grupo alquilamino C₁₋₂₀ sustituido o no sustituido, un grupo arilo C₆₋₂₀ sustituido o no sustituido, un grupo heteroarilo C₁₋₂₀ sustituido o no sustituido, -N(Q¹)(Q²), -C(=O)(Q¹), -N-C(=O)(Q¹), -N-C(=O)-N(Q¹)(Q²), -O-C(=O)(Q¹), -S(=O)(Q¹), -S(=O)₂(Q¹), -P(=O)(Q¹)(Q²) y -N-C(=NH)-N(Q¹)(Q²), cuando R¹(s) o R²(s) es(son) opcionalmente dos o más, dos de R¹(s) o R²(s) son sustituyentes en dos átomos adyacentes del anillo que están conectados de manera consecutiva a un anillo correspondiente, dos sustituyentes adyacentes R¹(s) o R²(s) están conectados entre sí para formar un grupo carbocíclico C₃₋₃₀ sustituido o no sustituido o un grupo heterocíclico C₁₋₃₀ sustituido o no sustituido, para formar de esta manera un anillo condensado con el anillo correspondiente; R³ y R⁴ opcionalmente están unidos para formar un grupo heterocíclico C₁₋₃₀ sustituido o no sustituido con un nitrógeno de la amida de la fórmula 1; k es un número entero de 0 a 4; cuando k es 2 o más, al menos dos R¹(s) son idénticos o diferentes entre sí, y m es un número entero de 0 a 7; cuando m es 2 o más, al menos dos R²(s) son idénticos o diferentes entre sí; donde cada uno de Q¹ y Q² se selecciona independientemente entre hidrógeno, halógeno, un grupo hidroxi, un grupo alquilo C₁₋₁₀ sustituido o no sustituido, un grupo alquenilo C₂₋₁₀ sustituido o no sustituido, un grupo alquinilo C₂₋₁₀ sustituido o no sustituido, un grupo cicloalquilo C₃₋₁₀ sustituido o no sustituido, un grupo heterocicloalquilo C₁₋₁₀ sustituido o no sustituido, un grupo alcoxi C₁₋₁₀ sustituido o no sustituido, un grupo cicloalcoxi C₃₋₁₀ sustituido o no sustituido, un grupo alquiltio C₁₋₁₀ sustituido o no sustituido, un grupo ariloxi C₆₋₁₀ sustituido o no sustituido, un grupo ariltio C₆₋₁₀ sustituido o no sustituido, un grupo heteroariloxi C₁₋₁₀ sustituido o no sustituido, un grupo heteroariltio C₁₋₁₀ sustituido o no sustituido, un grupo alquilamino C₁₋₁₀ sustituido o no sustituido, un grupo arilo C₆₋₁₀ sustituido o no sustituido y un grupo heteroarilo C₁₋₁₀ sustituido o no sustituido. Reivindicación 11: Un compuesto representado por la fórmula (2), un isómero óptico, un solvato o un tautómero o una sal farmacéuticamente aceptable de este, caracterizado porque, en la fórmula (2), A es hidrógeno o un grupo alquilo C₁₋₄; cada uno del o los W(s) es independientemente halógeno; n es un número natural entre 1 y 4; Y es un grupo cicloalquilo C₃₋₆ sustituido o no sustituido, un grupo pirrolidinilo sustituido o no sustituido unido a través de N, o un grupo piperidinilo sustituido o no sustituido unido a través de N, donde el grupo cicloalquilo C₃₋₆ sustituido es un grupo cicloalquilo C₃₋₆ en el cual al menos un hidrógeno está sustituido con un grupo funcional, cada uno de los cuales se selecciona independientemente entre halógeno y un grupo hidroxi, y cada uno del grupo pirrolidinilo sustituido unido a través de N y el grupo piperidinilo sustituido unido a través de N es un grupo pirrolidinilo unido a través de N y un grupo piperidinilo unido a través de N, respectivamente, en los cuales al menos un átomo de hidrógeno del anillo ha sido sustituido por un grupo funcional, cada uno de los cuales se selecciona independientemente entre un grupo alquilo C₁₋₄, halógeno, un grupo alcoxi C₁₋₄, un grupo hidroxi y un grupo heterocíclico C₁₋₁₀; y Z es un grupo pirrolidinilo sustituido o no sustituido unido a través de N, un grupo piperidinilo sustituido o no sustituido unido a través de N o un grupo azepanilo sustituido o no sustituido unido a través de N, donde al menos un sustituyente del grupo pirrolidinilo sustituido unido a través de N, el grupo piperidinilo sustituido unido a través de N o el grupo azepanilo sustituido unido a través de N se selecciona entre un grupo amino, un grupo alquilamino C₁₋₄, un grupo alquilo C₁₋₄, halógeno, un grupo alcoxi C₁₋₄ y un grupo heterocíclico C₁₋₁₀.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170117226 | 2017-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112900A1 true AR112900A1 (es) | 2019-12-26 |
Family
ID=65723753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102593A AR112900A1 (es) | 2017-09-13 | 2018-09-12 | Compuesto derivado de pirazol y uso de este |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11254676B2 (es) |
| EP (1) | EP3681877B1 (es) |
| JP (1) | JP7181287B2 (es) |
| KR (1) | KR102284205B1 (es) |
| CN (1) | CN111094265B (es) |
| AR (1) | AR112900A1 (es) |
| TW (1) | TWI794294B (es) |
| WO (1) | WO2019054766A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114105950B (zh) * | 2020-08-31 | 2022-09-06 | 南京明德新药研发有限公司 | 吡唑类化合物及其应用 |
| KR20230167102A (ko) | 2021-04-08 | 2023-12-07 | 오리존 지노믹스 에스.에이. | 골수성 암 치료를 위한 lsd1 억제제의 조합물 |
| EP4419504A4 (en) * | 2021-10-18 | 2025-09-03 | Imago Biosciences Inc | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE |
| CN116768797A (zh) * | 2022-03-16 | 2023-09-19 | 成都苑东生物制药股份有限公司 | 一种吡唑类衍生物、其制备方法及用途 |
| JP2025516648A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法 |
| WO2023217758A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| WO2024137358A1 (en) * | 2022-12-23 | 2024-06-27 | Imago Biosciences, Inc. | Kdm1a inhibitors for the treatment of disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| AU2004200420A1 (en) | 2003-03-11 | 2004-09-30 | Astellas Pharma Inc. | Inhibitor of cyclooxygenase |
| TW200526641A (en) | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| EP1928859A1 (en) * | 2005-06-17 | 2008-06-11 | Carex SA | Pyrazole derivates as cannabinoid receptor modulators |
| US7872006B2 (en) * | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| US9133128B2 (en) * | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| JP6430512B2 (ja) | 2013-12-11 | 2018-11-28 | セルジーン クオンティセル リサーチ，インク． | リジン特異的デメチラーゼ−１の阻害剤 |
| US10414750B2 (en) * | 2014-07-03 | 2019-09-17 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) * | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| PL3381896T3 (pl) | 2015-11-27 | 2023-05-08 | Taiho Pharmaceutical Co., Ltd. | Związek bifenylowy lub jego sól |
-
2018
- 2018-09-12 AR ARP180102593A patent/AR112900A1/es unknown
- 2018-09-12 TW TW107132109A patent/TWI794294B/zh active
- 2018-09-13 US US16/646,883 patent/US11254676B2/en active Active
- 2018-09-13 KR KR1020180109856A patent/KR102284205B1/ko active Active
- 2018-09-13 CN CN201880059878.9A patent/CN111094265B/zh active Active
- 2018-09-13 JP JP2020515066A patent/JP7181287B2/ja active Active
- 2018-09-13 EP EP18856659.0A patent/EP3681877B1/en active Active
- 2018-09-13 WO PCT/KR2018/010741 patent/WO2019054766A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020533372A (ja) | 2020-11-19 |
| CN111094265A (zh) | 2020-05-01 |
| CN111094265B (zh) | 2023-07-25 |
| KR102284205B1 (ko) | 2021-08-02 |
| US11254676B2 (en) | 2022-02-22 |
| US20210009591A1 (en) | 2021-01-14 |
| TWI794294B (zh) | 2023-03-01 |
| JP7181287B2 (ja) | 2022-11-30 |
| TW201920135A (zh) | 2019-06-01 |
| EP3681877B1 (en) | 2024-10-16 |
| WO2019054766A1 (en) | 2019-03-21 |
| EP3681877A1 (en) | 2020-07-22 |
| EP3681877C0 (en) | 2024-10-16 |
| EP3681877A4 (en) | 2021-02-24 |
| KR20190030192A (ko) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| PE20231935A1 (es) | Moduladores de la via de estres integrada | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| AR114236A1 (es) | Inhibidores de la gcn2 y usos de los mismos | |
| AR091976A1 (es) | Inhibidores de proteasa ns3 de vhc | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR110405A1 (es) | Compuestos | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| DOP2011000061A (es) | Compuestos de pirrol | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| MX2018002242A (es) | Compuestos de piperidinobenzodiazepina con actividad antiproliferativa. | |
| AR104555A1 (es) | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
| AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) |